Influence of GSTP1 Polymorphism on the Clinical Outcomes of Patients With Advanced NSCLC Receiving First-Line Bevacizumab-Based Regimen: A Real-World Retrospective Study

Fei Han*, Hanji Tian*, Baoli Jin and Gang Chen
Department of Thoracic Surgery, Shanxi Cancer Hospital, Taiyuan, P.R. China.

ABSTRACT

BACKGROUND: This study was to investigate the influence of GSTP1 gene polymorphism on the clinical outcomes of patients with advanced non-small-cell lung cancer (NSCLC) receiving first-line bevacizumab plus chemotherapy regimen.

METHODS: A total of 128 patients with advanced NSCLC who were administered with bevacizumab-based first-line regimens were recruited in this study. Available blood specimen and peripheral blood mononuclear cells (PBMCs) of the patients were obtained for the analysis of polymorphism and GSTP1 gene mRNA expression, respectively. The association between genotype status and clinical outcomes and other variates was analyzed and presented.

RESULTS: The prevalence of rs1695 was in accordance with Hardy-Weinberg Equilibrium (P = .978). Patients with GG and AG genotypes were merged in a pattern of dominant inheritance to seek for the potentially clinical significance. Analysis of efficacy exhibited that the objective response rate (ORR) of patients with AA genotype and AG/GG genotypes were 62.1% (54/87) and 51.2% (21/41) (P = .245). Prognosis demonstrated that the median progression-free survival (PFS) of patients with AA genotype and AG/GG genotypes were 9.5 and 5.6 months, respectively (P = .007). Furthermore, the median overall survival (OS) of the two genotypes were 22.0 and 16.6 months, respectively (P = .003). In addition, adjusted in multivariate Cox analysis for OS, AG/GG genotype was an independent factor for OS. Interestingly, mRNA analysis suggested that the mRNA expression of GSTP1 in PBMC of the patients with AG/GG genotypes of rs1695 polymorphism was significantly higher than those of patients with AA genotype (P < .001).

CONCLUSION: GSTP1 polymorphism rs1695 could be used for the prognostic evaluation of patients with advanced NSCLC receiving bevacizumab combined chemotherapy regimen.

KEYWORDS: Non-small cell lung cancer, bevacizumab, GSTP1, polymorphism, clinical outcome

Introduction

Lung cancer is reported to be the most common solid tumor with the highest morbidity and mortality all over the world. As the most common histological category, non-small-cell lung cancer (NSCLC) accounts for approximately 85% in lung cancer.1 Most patients were diagnosed with locally advanced or metastatic disease in China.2 Recent years had witnessed remarkable achievements regarding the therapy of programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors and targeted drugs for estimated glomerular filtration rate (EGFR), ALK, and ROS1, thus contributing to the significant survival benefits for the patients dramatically.3 However, approximately 50% of patients with advanced NSCLC were still absent of useful driver targets and became a research hotspot currently.4

Inhibition of angiogenesis could be used as a highly potent anticancer therapeutic approach and intensified the research for agents to hamper vessel formation in numerous cancers recently.5 Consequently, the antiangiogenic targeted drug bevacizumab combined with chemotherapy in the first-line setting for patients with advanced NSCLC exhibited superior progression-free survival (PFS) and improved OS.6,7 However, the objective response rate (ORR) of the first-line platinum-based chemotherapy regimens for advanced NSCLC was less than 30%,8 addition of bevacizumab could improve the ORR to approximately 50%.9 Still and all, great individual difference was observed clinically.10 And potential biomarkers that might predict the clinical outcomes of bevacizumab in patients with advanced NSCLC were needed currently.

Glutathione S-transferases (GSTs) family was composed of eight isoforms that were reported to detoxify the xenobiotic substrates by catalyzing their conjugation to reduced glutathione. Among them, glutathione S-transferase P 1 (GSTP1) was the most widely studied isoform in various disease.11 Glutathione S-transferase P 1 is located at 11q13.2, contains 7 exons and is of 3.2 kb in length with the ability to protect cells from carcinogens and cytotoxins. Discrepancy regarding the Glutathione S-transferases (GSTs) family was composed of eight isoforms that were reported to detoxify the xenobiotic substrates by catalyzing their conjugation to reduced glutathione. Among them, glutathione S-transferase P 1 (GSTP1) was the most widely studied isoform in various disease.11 Glutathione S-transferase P 1 is located at 11q13.2, contains 7 exons and is of 3.2 kb in length with the ability to protect cells from carcinogens and cytotoxins. Discrepancy regarding the GSTP1 gene played an important role in biodetoxification or

*Fei Han and Hanji Tian equal contribution to the work.
biotransformation by binding to reduced glutathione. As one of the phase-II metabolizing enzymes, GSTP1 was reported to catalyze detoxifying endogenous reactions with GSH and protect cellular macromolecules from damage caused by a wide variety of endogenous and exogenous molecules, including chemotherapeutic agents. Therefore, GSTP1 were crucial for the cell defense system. And these phase-II detoxification enzymes were involved in the detoxification of a variety of chemotherapeutics including platinum and exogenous molecules such as bevacizumab. In vitro analysis revealed a significant association between high GSTP1 expression of tumor cells and decreased sensitivity to platinum agents. And glutathione-conjugated exogenous molecules might be quickly excreted from tumor cell. Thus, it was plausible that high GST activity might result in more rapid metabolism that diminished the cytotoxic effects of chemotherapy on tumor cell. Interestingly, a recent study investigated the correlation between genetic variations of GSTP1 and clinical outcome of platinum-based chemotherapy in advanced NSCLC and concluded that rs1695 polymorphisms might contribute to the platinum-induced clinical outcomes in terms of both toxicity and therapeutic response variations. Furthermore, a previous meta-analysis study included a total of 23 published studies had indicated that GG genotype of GSTP1 IIe105Val polymorphism predicted superior therapeutic response to cisplatin-based chemotherapy among patients with NSCLC. Collectively, the above researches suggested that GSTP1 polymorphism could be of potentially clinical significance to predict the efficacy of chemotherapy for patients with NSCLC clinically.

Therefore, the aim of this study was to investigate the implication of GSTP1 polymorphism on the clinical outcomes of patients with advanced NSCLC receiving bevacizumab-based regimens in first-line setting.

**Patients and Methods**

**Study design and patient enrollment**

Bevacizumab was approved in China more than 10 years and covered in the national medical insurance directory recently. Consequently, a large number of patients with advanced or recurrent NSCLC were able to receive bevacizumab plus chemotherapy regimen clinically. In addition, correlation analysis between GSTP1 polymorphism and clinical outcome of the bevacizumab-based regimen was also performed in this study, which indicated that biological specimens had to be collected from the patients to identify the genotyping results of the polymorphism accordingly. Therefore, this study was designed as a real-world retrospective study just as the previous polymorphism study regarding bevacizumab-based therapy did.

Patients with advanced or recurrent NSCLC who were administered with bevacizumab-based regimens as first-line therapy from January 2016 to October 2020 in the department of thoracic surgery of Shanxi Cancer Hospital were participated in this study. This study was undertaken in accordance with good clinical practice guidelines and the protocol was approved by the ethics committees of Shanxi Cancer Hospital (approved number: KY2020136). All the patients enrolled were provided with the informed consent in accordance with the recommendations of the Declaration of Helsinki.

The main inclusion criteria and exclusion criteria were adopted according to the previous retrospective study initiated by N Geng and colleagues. Flow chart in Figure 1 illustrated the procedure in this study specifically. And 128 patients with advanced or recurrent NSCLC was included in this study. The primary analysis of this study was to explore the association between GSTP1 polymorphism genotype status and clinical outcomes of patients receiving bevacizumab combined with chemotherapy regimen.

**Treatment regimens and assessment of efficacy**

All the patients included were administered with bevacizumab combined with platinum-based chemotherapy regimen in first-line setting. Chemotherapy regimens consisted of pemetrexed or platinum or paclitaxel or docetaxel in combination with platinum drugs (carboplatin or cisplatin). And the specific usage and dosage of chemotherapy and bevacizumab was similar with the previous study.

Tumor response among the 128 patients was performed using RECIST version 1.1 criteria by investigator assessment. The drug response regarding the target lesions was assessed based on computed tomography (CT) scans every two cycles or depended on the actual situation when the clinical symptom of patients was getting worse. And the combination regimens could be terminated when potential life-threatening toxic reactions were observed.

**Distinguish of genotyping for GSTP1 rs1695 polymorphism**

Genomic DNA was extracted from the available biological specimens (mainly peripheral blood) using phenol-chloroform method and then stored at −20°C for subsequent usage. The polymorphisms of GSTP1 gene were selected according to the previous reports that the polymorphism of GSTP1 was of clinical significance, which were rs4891, rs749174, and rs1695. However, it seemed that only rs1695 was significantly associated with PFS in the preliminary analysis. As a result, this study implemented the analysis between rs1695 and clinical outcomes accordingly. Rs1695 was genotyped using restriction fragment length polymorphisms polymerase chain reaction (PCR-RFLP). The size of PCR product that included rs1695 was 286bp. Forward primer was 5'-CCCCAGTGACTGTTGTTTA-3', the reverse primer was 5'-GACACCTTGACCAAGAAGA-3'. A total of 2 μL PCR products were digested using the restriction enzyme BsmBI (Thermo Fisher Scientific, USA). Using the following band to distinguish the genotypes: AA genotype (one
286 bp band); AG genotype (three bands: one 286 bp band, one 150 bp band and one 136 bp band); GG genotype (two bands: one 150 bp band and one 136 bp band).

Collection of peripheral blood mononuclear cell specimen and GSTP1 gene mRNA expression analysis

Given that GSTP1 gene was related to the pharmacokinetics of chemotherapeutic drugs rather than the gene of tumor predisposition and development, we chose peripheral blood mononuclear cell (PBMC) specimen instead of tumor tissue to investigate the GSTP1 gene mRNA expression. Therefore, the matched PBMC specimens were selected from 86 samples originally. Nevertheless, as presented in Figure 1, extraction of PBMC specimens from 11 patients was not successful and 7 patients failed the RNA extraction. Therefore, a total of 68 specimens were available for GSTP1 mRNA expression analysis. The procedure of RNA extraction and mRNA expression experiment was performed according to the previous study. Forward primer of GSTP1 gene was 5’-GTAGTTTGCCCAAGGTCAAG-3’, the reverse primer was 5’-AGCCACCTGAGGGGTAAG-3’. In addition, GSTP1 mRNA expression status was divided into GSTP1 high expression (GSTP1H) and GSTP1 low expression (GSTP1L) according to the median GSTP1 mRNA relative expression to identify the potential association with OS.

Statistical analysis

SPSS software version 25.0 was used to performed all the data analysis in this study. Chi-square test and Mann–Whitney U test nonparametric for the respective variables according to rs1695 genotype status was used appropriately. Definition of efficacy endpoints regarding ORR and disease control rate (DCR) was adopted according to the previous study. Stata 14.0 was used to present the Kaplan–Meier survival curves for PFS and OS according to the genotype status of rs1695. Difference between the survival curve was calculated using the log-rank test. Definition of prognostic endpoints regarding PFS and OS was used on the basis of previous work. Cox regression analysis was adopted for OS for multivariable analysis. \( P < .05 \) was accepted as statistical difference.

Results

Baseline characteristics

Baseline characteristics of the 128 patients with NSCLC enrolled were exhibited in Table 1. Patients included were the
common NSCLC patients clinically. And it should be noted that majority of initial dosage of bevacizumab was 7.5 mg/kg (93.8%).

Genotyping results of rs1695 polymorphism

rs1695 polymorphism was of clinical significance in the association analysis. The prevalence of rs1695 among the 128 patients with NSCLC were: AA genotype 87 cases (68.0%), AG genotype 37 cases (28.9%), GG genotype 4 cases (3.1%). Minor allele frequency of rs1695 is 0.18. The distribution of three genotypes were in accordance with Hardy–Weinberg equilibrium (P = .978). Given that patients with GG genotype was rare, patients with GG and AG genotypes were merged in a pattern of dominant inheritance to seek for the potentially clinical significance. As illustrated in Table 1, the baseline characteristics of patients with AA and AG/GG genotypes were similar and comparable (P > .05).

Influence of GSTP1 rs1695 polymorphism on the efficacy and prognosis of the patients

Given that this study was designed as a retrospective study, the imaging evidence regarding the target lesions of the patients was collected and analyzed retrospectively. The best drug response assessment indicated that complete response (CR) was observed in 0 patients, partial response (PR) was noted in 75 patients, stable disease (SD) was seen in 42 patients, and progressive disease (PD) was reported in 11 patients. Consequently, ORR and DCR of the 128 patients with NSCLC was 58.6% (95% CI: 49.6%–67.2%) and 91.4% [117/128] [95% CI: 85.1%–95.6%], respectively. As illustrated in Figure 2, the ORR of patients with AG/GG genotype and AA genotype were 51.2% [95% CI: 35.1%–67.1%] and 62.1% [95% CI: 51.0%–72.3%], respectively [P = .245]. The DCR of patients with AG/GG genotype and AA genotype were 85.4% [95% CI: 70.8%–94.4%] and 94.3% [95% CI: 87.1%–98.1%], respectively [P = .094].

Data cut-off date of this study was February 2021, and the median follow-up duration of the patients was 18.5 months (follow-up range: 0.5–36 months). Regarding PFS data, a total of 109 patients were observed the PFS events or death events when the data were cutoff. Therefore, the PFS data maturity was 85.2%. As illustrated in Figure 3, the median PFS of the 128 patients was 8.2 months (95% CI: 6.70–9.70). In addition, majority patients were available for the death status. And a total of 84 patients were noted the death events when the data were cutoff, and the OS data maturity was 65.6%. As exhibited in Figure 3, the median OS of the 128 patients with advanced NSCLC was 19.9 months (95% CI: 18.30–21.50).

Association analysis between rs1695 polymorphism status and prognosis was exhibited in Figure 4A, the median PFS of patients with AA and AG/GG genotype was 9.5 months (95% CI: 7.99–11.01) and 5.6 months (95% CI: 3.35–7.85), respectively, which was statistically significant (χ² = 7.237, P = .007). Furthermore, as exhibited in Figure 4B, the median OS of patients with AA and AG/GG genotype was 22.0 months (95% CI: 19.74–24.26) and 16.6 months (95% CI: 10.92–22.28), respectively. And the difference was statistically significant (χ² = 8.763, P = .003). Separately, median OS of patients with AA, AG, and GG genotype was 22.0 (95% CI: 19.74–24.26), 16.6 (95% CI: 9.95–23.25), and 10.0 (95% CI: 0.00–22.74) months, respectively. And the difference was statistically significant as well (χ² = 10.47, P = .005).

Multivariate Cox regression analysis was introduced to for OS. Univariate analysis between baseline characteristics and OS was performed first. As illustrated in Table 2, age, Eastern Cooperative Oncology Group (ECOG) score and genotype of rs1695 were of positive correlation with OS in the univariate analysis. Therefore, these variables were included in the multivariate Cox regression analysis accordingly. Multivariate analysis results were presented in Table 2, rs1695 polymorphism status was an independent factor for OS (hazard ratio [HR] = 0.76 [95%CI: 0.55–0.85], P = .008) after multivariate adjustment. Besides, other statistically significant variables in the multivariate Cox analysis were age (HR = 0.82, P = .011) and ECOG score (HR = 0.73, P = .009).

In addition, we further reanalyzed the therapeutic data regarding the second- and third-line therapy regimens among the available patients. A total of 75 patients (58.6%) had received second-line therapeutic regimens and a total of 49 patients (38.3%) had received third-line treatment. The most common second-line therapy was chemotherapy alone regimen and the most common third-line therapeutic treatment was anlotinib regimen. And the association analysis between GSTP1 rs1695 genotype status and therapeutic regimens failed to find significant difference (P > .05).

Association between rs1695 genotype status and mRNA expression of GSTP1

Expression of GSTP1 mRNA was determined by extracting RNA from 68 PBMC specimens, and the correlation between the genotype status of rs1695 and mRNA expression was analyzed. First, the prevalence of rs1695 polymorphism in the 68 PBMC specimens were AA genotype 46 cases (67.6%), AG genotype 19 cases (27.9%), and GG genotype 3 cases (4.4%). The MAF was 0.18 and distribution frequency of the three genotypes also accorded with the Hardy–Weinberg equilibrium (P = .570) and were comparable with that among the 128 patients. Similarly, AG and GG genotypes were merged in the subsequent analysis. As illustrated in Figure 5, the relative expression of GSTP1 mRNA in PBMC of patients with AG/GG genotype was significantly higher than that of patients with AA genotype of rs1695 polymorphism (3.96 ± 0.511 vs 2.81 ± 0.820), which was statistically significant (t = 6.033, P < .001).
Furthermore, patients with GSTP1H and GSTP1L were observed in 35 cases and 33 cases, respectively. As exhibited in Figure 6, the median OS of patients with GSTP1H and patients with GSTP1L was 18.0 months and 20.0 months, respectively. And the difference had a trend for marginally significant ($\chi^2 = 3.445, P = .063$).

| CHARACTERISTICS | TOTAL (N = 128, %) | RS1695 GENOTYPE STATUS | $\chi^2$ | $P$ |
|----------------|-------------------|------------------------|---------|-----|
|                |                   | AA (N=87)              | AG/GG (N=41) |       |     |
| Age (year)     |                   |                        |          |     |
| Median (range) | 61 (21-83)        | 60 (21-79)             | 61 (29-83) | NA   | .532|
| Gender         |                   |                        |          |     |
| Male           | 91 (71.1)         | 61 (70.1)              | 30 (73.2) | 0.127| .722|
| Female         | 37 (28.9)         | 26 (29.9)              | 11 (26.8) |      |     |
| ECOG score     |                   |                        |          |     |
| 0              | 49 (38.3)         | 33 (37.9)              | 16 (39.0) | 0.014| .905|
| 1-2            | 79 (61.7)         | 54 (62.1)              | 25 (61.0) |      |     |
| Pathological staging | | | | |
| IIIb           | 9 (7.0)           | 6 (7.0)                | 3 (7.3)   | 0.303| .927|
| IV             | 108 (84.4)        | 74 (85.1)              | 34 (82.9) |      |     |
| Recurrent      | 11 (8.6)          | 7 (8.0)                | 4 (9.8)   |      |     |
| Smoking status |                   |                        |          |     |
| Non smoker/former smoker | 92 (71.9) | 60 (69.0)              | 32 (78.0) | 1.137| .286|
| Smoker         | 36 (28.1)         | 27 (31.0)              | 9 (22.0)  |      |     |
| Histological type |                 |                        |          |     |
| Adenocarcinoma | 111 (86.7)        | 75 (86.2)              | 36 (87.8) | 0.062| .804|
| Other types    | 17 (13.3)         | 12 (13.8)              | 5 (12.2)  |      |     |
| Driver gene mutation status* | | | | |
| Positive       | 19 (14.8)         | 13 (14.9)              | 6 (14.6)  | 0.096| .953|
| Negative       | 89 (69.5)         | 61 (70.1)              | 28 (68.3) |      |     |
| NA             | 20 (15.7)         | 13 (14.9)              | 7 (17.1)  |      |     |
| Combined chemotherapy regimens | | | | |
| Cisplatin-based regimens | 56 (43.8) | 38 (43.7)              | 18 (43.9) | 0.001| .981|
| Carboplatin-based regimens | 72 (56.2) | 49 (56.3)              | 23 (56.1) |      |     |
| Combined chemotherapy regimen | | | | |
| Pemetrexed     | 76 (59.4)         | 53 (60.9)              | 23 (56.1) | 0.465| .793|
| Docetaxel      | 31 (24.2)         | 21 (24.1)              | 10 (24.4) |      |     |
| Paclitaxel     | 21 (16.4)         | 13 (14.9)              | 8 (19.5)  |      |     |
| Initial dosage of bevacizumab (mg/kg) | | | | |
| 7.5            | 120 (93.8)        | 83 (95.4)              | 37 (90.2) | 1.266| .267|
| 15             | 8 (6.2)           | 4 (4.6)                | 4 (9.8)   |      |     |

Abbreviations: ECOG, Eastern Cooperative Oncology Group; GSTP1, glutathione S-transferase P 1; NA, not available; NSCLC, non-small cell lung cancer.

*The driver gene were EGFR mutation or ALK fusion.
To our knowledge, target of bevacizumab was angiogenic signal pathway instead of tumor-driven signal pathways, which was a host-mediated process based on an individual's unique inherited genomic profile. Consequently, it was necessary to use the germline DNA to identify potential biomarkers of bevacizumab-based regimen.24 Furthermore, the heterogeneous nature of NSCLC had witnessed considerable discrepancy regarding the clinical outcomes of NSCLC therapy clinically.25 Bevacizumab was proved to be of potential clinical activity for patients with NSCLC according to ECOG 4599 and AVAIL clinical trials.7,26 In addition, genetic variation of vascular endothelial growth factor (VEGF) pathway was proved to play an important role to predict the efficacy of antiangiogenic targeted drugs.27 Fortunately, we found that Maria Gaibar and colleagues explored in 2021 that polymorphisms of angiogenesis pathway genes (ANGPT1, CD39, FGF2, and MMP9) were associated with clinical outcome of bevacizumab plus chemotherapy for metastatic colorectal cancer.19 EJ Lewintre and colleagues reported recently that polymorphism of VEGFR-1 and VEGF-A and plasma levels of VEGF-A predicted the efficacy and prognosis of patients with nonsquamous NSCLC receiving chemotherapy combined with bevacizumab administration.28 Collectively, polymorphism in the gene at the pathway single of bevacizumab disposition was proved to be of certain clinical significance for bevacizumab-based regimen.

With regard to the efficacy and prognosis of the total patients, ORR of the 128-patient cohort was 58.6%, DCR was 91.4%, the median PFS was 8.2 months, and the median OS was 19.9 months, which was inferior to the clinical outcome of the BEYOND clinical trial numerically.6 One possible interpretation could be owing to the retrospective design of our study. Management and adherence of the patients in our...
research was poor compared with well-designed phase-III clinical trial, which had been proved previously. Another reasonable explanation might be that patients with ECOG performance status 2 score were also included in our study and higher ECOG performance status score was correlated with worse prognosis. Collectively, the real-world evidence among the 128 patients with NSCLC demonstrated that bevacizumab combined with platinum-based regimen exhibited satisfactory clinical outcomes.

Furthermore, it seemed that our study might be the first study that explored the relevance of efficacy of bevacizumab-based regimens to GSTP1 gene polymorphism in Chinese population. Interestingly, a previous exploratory study initiated by Celine P and colleagues investigated the association between VEGF polymorphisms and clinical outcomes of first-line bevacizumab plus chemotherapy for patients with nonsquamous NSCLC. The conclusion indicated that four polymorphisms of VEGFA were associated with bevacizumab therapeutic outcomes. Therefore, these data exhibited the potential predictive significance of polymorphism in antiangiogenic single pathway for the efficacy and prognosis of patients receiving bevacizumab-based regimen. With regard to GSTP1 gene polymorphism, the previous study initiated by HY Lv and colleagues explored the clinical implication of genetic polymorphism of GSTP1 and ERCC1 in patients with NSCLC receiving platinum-based chemotherapy. And the results indicated that patients with AG/GG genotype of GSTP1 were associated with superior clinical outcome, which was inconsistent with that in our study. We speculated that the discrepancy could be attributed to the heterogeneity of subjects included and the treatment regimens. However, another retrospective initiated by ZJ Yuan and colleagues investigated the association of GSTP1 and response of gemcitabine-cisplatin chemotherapy in Chinese patients with NSCLC. The results suggested that A genotype carriers were significantly higher in sensitive group than in nonsensitive group, which was consistent with that in our study to some extent. Unfortunately, the two studies failed to investigate the association between the genotype status of the polymorphism and GSTP1 gene mRNA expression. Interestingly, it should be noted that patients with positive driver gene mutation (mainly EGFR mutation) conferred a longer OS (median OS: 20.9 vs 19.1 months) than those with other status of driver gene mutation numerically, even the difference was not statistically significant \((P=0.377)\). Previous study suggested that expression of VEGFA level was increased in EGFR mutation NSCLC compared with EGFR-wild type. As a result, we noticed that recent study found patients with EGFR-positive mutation could benefit from bevacizumab combined with platinum-based chemotherapy in NSCLC with EGFR mutation, which was consistent with the results in our study to some extent. Furthermore, to our knowledge, PD-1/PD-L1 blockades might be useless for patients harboring positive EGFR mutation previously. However, according to the IMpower150 clinical trial, bevacizumab combined with atezolizumab plus carboplatin plus paclitaxel (ABCP) regimen significantly improved PFS for patients with EGFR-mutated NSCLC, which suggested that the addition of bevacizumab to other drugs could be beneficial for patients with positive EGFR mutation NSCLC. Collectively, NSCLC with positive EGFR mutation who harbored GSTP1 rs1695 AA genotype might benefit from bevacizumab combined with chemotherapy regimen significantly. And the conclusion should be confirmed in large-scale prospective clinical trials subsequently.

Interestingly, mRNA expression of GSTP1 disclosed that patients with AG/GG genotype of rs1695 were associated with higher GSTP1 mRNA expression. Previous work had elucidated that GSTP1 gene could contribute to the function of bio-interpretation or biotransformation by binding to reduced glutathione appropriately. We speculated that the reason why
higher GSTP1 mRNA expression conferred worse prognosis could be attributed that higher GSTP1 mRNA expression might reduce the level of drugs in tumor cells, thus compromising the efficacy of bevacizumab-based therapeutic regimen directly. In addition, located at coding area of GSTP1 gene, rs1695 polymorphism resulted in the alteration of amino acid from isoleucine to valine, which might compromise the expression and function of GSTP1 gene to some extent. At present, the association between GSTP-1 gene expression level and prognosis of patients was still controversial. Previous study initiated by FM Yang and colleagues performed the research among patients with primary epithelial ovarian cancer (EOC) to investigate the prognostic significance of GSTP1 gene expression. And the results supported that higher expression of GSTP1 predicted worse prognosis among patients with EOC, which was consistent with the mRNA expression results in our study. However, another exploratory study reported in 2017 initiated by XJ Liu and colleagues performed the analysis of 128 patients with non-small cell lung cancer (NSCLC) to investigate the relationship between GSTP1 polymorphism and overall survival. The results of this study are summarized in Table 2.

Table 2. Overall survival of the 128 patients with NSCLC according to baseline characteristics and polymorphism in univariate analysis and multivariate Cox analysis.

| CHARACTERISTICS               | MEDIAN OS (95% CI) | P (UNIVARIATE ANALYSIS) | MULTIVARIATE ANALYSIS |
|------------------------------|-------------------|-------------------------|-----------------------|
|                              |                   |                         | HR (95% CI)           | P               |
| Age                          |                   |                         |                       |                 |
| <61                          | 21.4 (20.20-22.6) | 0.009                   | 0.82 (0.71-0.95)      | .011            |
| ⩾61                          | 17.5 (16.11-18.89)|                         |                       |                 |
| Gender                       |                   |                         |                       |                 |
| Male                         | 18.7 (17.12-20.28)| 0.325                   |                       |                 |
| Female                       | 20.5 (18.91-22.09)|                         |                       |                 |
| ECOG score                   |                   |                         |                       |                 |
| 0                            | 23.1 (20.98-25.22)| 0.007                   | 0.73 (0.49-0.82)      | .009            |
| 1-2                          | 17.0 (15.43-18.57)|                         |                       |                 |
| Smoking status               |                   |                         |                       |                 |
| Nonsmoker/former smoker      | 20.5 (18.65-22.35)| 0.411                   |                       |                 |
| Smoker                       | 19.1 (17.76-20.44)|                         |                       |                 |
| Histological type            |                   |                         |                       |                 |
| Adenocarcinoma               | 20.2 (18.11-22.29)| 0.515                   |                       |                 |
| Other types                  | 19.5 (18.32-20.68)|                         |                       |                 |
| Driver gene mutation         |                   |                         |                       |                 |
| Positive                     | 20.9 (18.88-22.92)| 0.377                   |                       |                 |
| Other status                 | 19.1 (17.98-20.22)|                         |                       |                 |
| Combined chemotherapy regimen|                   |                         |                       |                 |
| Cisplatin based              | 19.5 (18.11-20.89)| 0.638                   |                       |                 |
| Carboptatin based            | 20.3 (18.58-22.02)|                         |                       |                 |
| Initial dosage of bevacizumab (mg/kg) |   |                   |                       |                 |
| 7.5                          | 19.6 (18.12-21.08)| 0.515                   |                       |                 |
| 15                           | 20.2 (18.67-21.73)|                         |                       |                 |
| Genotypes of rs1695 polymorphism |         |                   |                       |                 |
| AA                           | 22.0 (19.74-24.26)| 0.003                   | 0.76 (0.55-0.85)      | .008            |
| AG/GG                        | 16.6 (10.92-22.28)|                         |                       |                 |

Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; NSCLC, non-small cell lung cancer; OS, overall survival.
between GSTP1 expression and prognosis of patients with hepatocellular carcinoma. The results indicated that higher GSTP1 levels could provide a superior PFS and OS through the suppression of tumorigenesis in HCC. This conclusion contradicted the results in our study, and the discrepancy could be related to the different significance of GSTP1 gene expression in different cancer. Collectively, patients with higher expression of GSTP1 conferred worse prognosis should be validated in large-scale prospective trials in the future.

From the objective view, some limitations could be unavoidable in our study. The small sample size and retrospective design of this study might compromise the conclusion in our study to some extent. And the prognostic data maturity regarding PFS and OS of the study was relatively low. Consequently, the conclusion in our study should be validated large-scale prospective trials further. Collectively, our study sufficiently performed the prognostic significance of rs1695 polymorphism and revealed part of the reasons for the prognostic difference caused by this polymorphism from the aspect of GSTP1 mRNA expression, which could be of clinical guiding significance for prognostic evaluation of bevacizumab-based first-line regimens in patients with advanced NSCLC.

**Conclusion**

Collectively, our retrospective study highlighted that GSTP1 polymorphism rs1695 could be used as a potential biomarker for the prognostic evaluation of patients with advanced NSCLC receiving bevacizumab-combined chemotherapy regimen.

**Acknowledgements**

The authors would like to express their sincere gratitude to the patients and their families for participating in this study. They thank all the staff who took part in this study.

**Author Contributions**

F.H. and G.C. designed the study and prepared this manuscript. F.H. and H.J.T. collected the data and conducted the statistics. F.H. and B.L.J. participated in the experiments and follow-up. All authors participated in the reviewed of the manuscript and approved the final manuscript.

**Ethical Approval**

This study was approved by the ethics committees of Shanxi Cancer Hospital (approval no: KY2020136).

**Informed Consent**

All patients in this study provided written informed consent.

---

**Figure 5.** Relative mRNA expression level of GSTP1 gene according to GSTP1 rs1695 genotype status. GSTP1 indicates glutathione S-transferase P 1; mRNA, messenger RNA.

**Figure 6.** Overall survival of the 68 patients with advanced non-small-cell lung cancer receiving bevacizumab plus chemotherapy regimens according to GSTP1 mRNA expression status. GSTP1 indicates glutathione S-transferase P 1; mRNA, messenger RNA; OS, overall survival.
REFERENCES

1. Zhang J, Mao W, Chen Z, Gu H, Lian C. Clinical significance of Has_circ_3060937 in bone metastasis of NSCLC. Int J Mol Sci. 2020;13:1115-1121.
2. Jahangiri M, Liu HM, Pan X, Yin Y, Baumann P, Langer CJ. Immunotherapy treatment patterns and outcomes among ALK-positive patients with non-small-cell lung cancer. Clin Lung Cancer. 2021;22:49-57.
3. Yuan M, Huang LL, Chen JH, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. 2019;4:61.
4. Feng Y, Feng G, Lu X, et al. Exploratory analysis of introducing next-generation sequencing-based method to treatment-naive lung cancer patients. J Thorac Dis. 2018;10:5904-5912.
5. Daum S, Hagen H, Naismith E, Wolf D, Pircher A. The role of anti–angiogen- eisis in the treatment landscape of non–small cell lung cancer—new combina- tional approaches and strategies of neovessel inhibition. Front Cell Dev Biol. 2020;8:610903.
6. Zhou C, Wu YL, Chen G, et al. BEYOND: a randomized, double-blind, pla- cebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent non- squamous non-small-cell lung cancer. J Clin Oncol. 2015;33:2197-2204.
7. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevaci- zumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-2550.
8. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non- small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819-1830.
9. Assoum S, Brosseau S, Steinmetz C, Gounant V, Zalcman G. Bevacizumab in ad- vanced non–small cell lung cancer: state of the art. Future Oncol. 2017;13:2515-2535.
10. Niki M, Yokoi T, Kurata T, Nomura S. New prognostic biomarkers and thera- peutic effect of bevacizumab for patients with non-small-cell lung cancer. Anticancer Res. 2015;35:1031-1037.
11. Farmohammadi A, Arab-Yarmohammadi V, Ramzanpour R. Association analy- sis of rs1695 and rs1138272 variations in GSTP1 gene and breast cancer sus- ceptibility. Asian Pac J Cancer Prev. 2020;21:3693-3702.
12. Zhou C, Wu YL, Chen G, et al. BEYOND: a randomized, double-blind, pla- cebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent non- squamous non-small-cell lung cancer. J Clin Oncol. 2015;33:2197-2204.
13. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevaci- zumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-2550.
14. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non- small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819-1830.
15. Assoum S, Brosseau S, Steinmetz C, Gounant V, Zalcman G. Bevacizumab in ad- vanced non–small cell lung cancer: state of the art. Future Oncol. 2017;13:2515-2535.
16. Niki M, Yokoi T, Kurata T, Nomura S. New prognostic biomarkers and thera- peutic effect of bevacizumab for patients with non-small-cell lung cancer. Anticancer Res. 2015;35:1031-1037.
17. Takeuchi A, Oguri T, Fukuda S, et al. Variants of SLC22A16 predict the effi- cacy of platinum combination chemotherapy in advanced non-small-cell lung cancer. Anticancer Res. 2020;40:603-613.
18. Ogura T, Fusaichi Y, Katoh O, et al. Glutathione S-transferase-pi gene expres- sion in the treatment landscape of non—small cell lung cancer—new combina- tional approaches and strategies of neovessel inhibition. Front Cell Dev Biol. 2020;8:610903.
19. Takeuchi A, Oguri T, Fukuda S, et al. Variants of SLC22A16 predict the effi- cacy of platinum combination chemotherapy in advanced non-small-cell lung cancer. Anticancer Res. 2020;40:603-613.
20. Geng N, Su J, Liu Z, Ding C, Xie S, Hu W. The influence of KDR genetic varia- tions of rs1695 and rs1138272 variations in GSTP1 gene and breast cancer sus- ceptibility. Asian Pac J Cancer Prev. 2020;21:3693-3702.
21. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
22. Yang F, Liu QM, Li LR. Association of GSTP1 and XRCC1 gene polymor- phisms with clinical outcomes of patients with advanced non-small cell lung can- cer. Genet Mol Res. 2015;14:1031-1037.
23. Takeuchi A, Oguri T, Fukuda S, et al. Variants of SLC22A16 predict the effi- cacy of platinum combination chemotherapy in advanced non-small-cell lung cancer. Anticancer Res. 2020;40:603-613.
24. Gal J, Milano G, Brest P, et al. VEGF-related germinal polymorphisms may identify a subgroup of breast cancer patients with favorable outcome under beva- cizumab-based therapy—a message from COMET, a French Unicancer Multi- centric Study. Pharmaceuticals (Basel). 2020;13:414.
25. Duma N, Santanu-Davila R, Molina JR. Non-small cell lung cancer—a review: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94:1623-1640.
26. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gem- citabine with either placebo or bevacizumab as first-line therapy for nonsqua- mous non-small-cell lung cancer. Avail. J Clin Oncol. 2009;27:1227-1234.
27. Liu JY, Zhu BR, Sun X. The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis. Int J Clin Oncol. 2020;25:1195-1205.
28. Pallaud C, Reck M, Jabahs E, et al. Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line beva- cizumab plus chemotherapy in non-squamous non-small-cell lung cancer. Lung Cancer. 2014;86:67-72.
29. Lv H, Han T, Shi X, et al. Genetic polymorphism of GSTP1 and ERCC1 cor- related with response to platinum-based chemotherapy in non-small cell lung cancer. Mol Oncol. 2014;8:1086.
30. Yuan ZJ, Zhou WW, Liu W, et al. Association of GSTP1 and RRM1 poly- morphisms with the response and toxicity of gemcitabine–cisplatin combination che- motherapy in Chinese patients with non-small cell lung cancer. Asian Pac J Clin Oncol. 2015;16:4347-4351.
31. Reimnuth N, Jauch A, Xu EC, et al. Correlation of EGFR mutations with chro- mosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor sam- ples of lung adenocarcinoma patients. Lung Cancer. 2008;62:193-201.
32. Takahashi I, Morise M, Miyawara A, et al. Potential benefits of bevacizumab combined with platinum-based chemotherapy in advanced non-small-cell lung cancer patients with EGFR mutation. Clin Lung Cancer. 2020;21:273-280.
33. Socinski MA, Jotte RM, Capuzzo F, et al. Atezolizumab for first-line treat- ment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288-2301.
34. Dong X, Sun R, Wang J, et al. Glutathione S-transferases P1-mediated interleu- kin-6 in tumor-associated macrophages augments drug-resistance in MCF-7 breast cancer. Biochem Pharmacol. 2018;122:41289.
35. Ferracin AC, Lopes-Aguiar L, Lourenço GJ, et al. GSTP1 and ABCB1 poly- morphisms predicting toxicities and clinical management on carboplatin and paclitaxel-based chemotherapy in ovarian cancer. Clin Transl Sci. 2021;14:720-728.
36. Yang F, Gao B, Chen W, et al. Expression of resistance gene and prognosis of chemotherapy in primary epithelial ovarian cancer. Medicine (Baltimore). 2018;97:e12164.
37. Liu X, Tan N, Liao H, et al. High GSTP1 inhibits cell proliferation by reducing Akt phosphorylation and is associated with a better prognosis in hepatocellular carcinoma. Oncotarget. 2018;9:8957-8971.